Johnson & Johnson said on Wednesday its experimental drug helped reduce symptoms of major depressive disorder (MDD) and insomnia in a late-stage trial when given along with commonly used antipsychotic treatments.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,